Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

AstraZeneca Secures Full Global Rights to AbelZeta’s C‑CAR031 in $630M CAR‑T Deal

Fineline Cube Jan 20, 2026
Company Deals

Medtronic and Precision Neuroscience Form First Brain‑Device Alliance to Access Neural Data

Fineline Cube Jan 20, 2026
Company Deals

Harbour BioMed Boosts Spruce Stake to 3.8%, Advancing SPR202 for Adrenal Disease

Fineline Cube Jan 19, 2026
Company Deals

InventisBio Files for Hong Kong IPO, Betting on Oncology and Metabolic Pipeline

Fineline Cube Jan 16, 2026
Company Deals

Boston Scientific to Acquire Penumbra in $14.5 Billion Deal, Bolsters Thrombectomy Leadership

Fineline Cube Jan 16, 2026
Policy / Regulatory

NHSA Releases NRDL Value Assessment Guidelines, Prioritizing 8 Drug Categories for Real‑World Evaluation

Fineline Cube Jan 15, 2026
Company Drug

Novartis’s Ianalumab Wins FDA Breakthrough Therapy Designation for Sjögren’s Disease

Fineline Cube Jan 20, 2026
Company Drug

Akeso’s Gumokimab NMPA Filing for Ankylosing Spondylitis Expands IL‑17A Franchise

Fineline Cube Jan 19, 2026
Company Legal / IP

Biocytogen Pharmaceuticals Awarded CNIPA Patent for RenMab Human Antibody Mice Platform

Fineline Cube Jul 12, 2023

Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315), a China-based biopharmaceutical company, has announced receiving a...

Company Deals Medical Device

Guangdong’s OptoMedic Secures Over $27.8 Million in Pre-IPO Financing for Endoscopy Innovations

Fineline Cube Jul 12, 2023

OptoMedic Technologies, Inc., a leading endoscopy specialist based in Guangdong, has reportedly raised upwards of...

Company Drug

Jiangsu Hengrui Pharmaceuticals’ Irinotecan and Bupivacaine Liposome Injections Get Clinical Trial Green Light in China

Fineline Cube Jul 12, 2023

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a China-based pharmaceutical company, has announced receiving separate...

Company Drug

Shanghai Junshi Biosciences’ Tuoyi Files for 9th Indication in China for RCC Treatment

Fineline Cube Jul 12, 2023

Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has announced that the National Medical...

Company Drug

Jiangsu Hengrui Pharmaceuticals Receives Clinical Trial Approvals for Irinotecan and Bupivacaine Liposome Injections

Fineline Cube Jul 12, 2023

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a China-based pharmaceutical company, has announced receiving separate...

Company Drug

Shanghai Junshi Biosciences’ Tuoyi Files for 9th Indication in China for RCC Treatment

Fineline Cube Jul 12, 2023

Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has announced that the National Medical...

Company Deals

Next Generation Gene Therapeutics Secures $40 Million in Series B Financing for Gene Therapy Development

Fineline Cube Jul 12, 2023

Next Generation Gene Therapeutics Inc., a leading gene therapy developer based in Suzhou, China, has...

Company Deals

Ji Xing Pharmaceuticals and TSH Biopharm Announce Collaboration for Dry Eye Treatment in Taiwan

Fineline Cube Jul 12, 2023

Shanghai-based Ji Xing Pharmaceuticals, a company backed by RTW Investments, has announced a strategic collaboration...

Company Drug

Hrain Biotechnology’s Anti-CD70 T Cell Therapy HR010 Gets Tacit Approval for Renal Cancer Trial

Fineline Cube Jul 12, 2023

Shanghai-based Hrain Biotechnology Co., Ltd. has announced receiving tacit clinical trial approval from the Center...

Company Drug

Huadong Medicine’s Elahere Receives Approval for FRα Positive Cancer Treatment in China

Fineline Cube Jul 12, 2023

China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced receiving approval to introduce Elahere (mirvetuximab...

Company Deals

WuXi Biologics Proposes Spin-Off and Listing of WuXi XDC on Hong Kong Stock Exchange

Fineline Cube Jul 11, 2023

China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced the...

Company Drug

Jiangxi Jemincare Group Launches Omalizumab Biosimilar CMAB007 in China for Asthma and Dermatology

Fineline Cube Jul 11, 2023

Jiangxi Jemincare Group has overseen the official launch and first prescription of its omalizumab biosimilar,...

Company Deals

Zhejiang Doer Biologics Partners with BioNTech for Global Development of Innovative Biological Drugs

Fineline Cube Jul 11, 2023

Zhejiang Doer Biologics Co., Ltd, a China-based clinical-stage biopharmaceutical company, has announced a significant licensing...

Company Drug

C4 Therapeutics’ CFT8919 Earns FDA Approval for Clinical Trials Targeting EGFR L858R Mutations

Fineline Cube Jul 11, 2023

US-based C4 Therapeutics Inc., (NASDAQ: CCCC) has announced receiving clinical trial approval from the US...

Policy / Regulatory

NHSA’s 2022 Report: BMI Fund Income Rises 7.6%, Outgoing Expenditure Increases 2.3%

Fineline Cube Jul 11, 2023

The National Healthcare Security Administration (NHSA) has released its annual statistical report for 2022, detailing...

Company Drug

Zai Lab’s Vyvgart Receives NMPA Review for Subcutaneous Injection Form in gMG Treatment

Fineline Cube Jul 11, 2023

China-based Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688) has announced that the National Medical Products...

Company Medical Device

Sino Medical Sciences Receives Approval for Next-Generation Drug-Eluting Stent in Indonesia

Fineline Cube Jul 11, 2023

China-based Sino Medical Sciences Technology Inc., (SHA: 688108) has announced receiving market approval for its...

Policy / Regulatory

Shanghai’s SMPA Initiates Volume-Based Procurement for National VBP Drugs in Alliance Region

Fineline Cube Jul 11, 2023

Shanghai’s Sunshine Medical Procurement All-in-One (SMPA) has released a notification indicating the commencement of follow-up...

Company Drug

Jiangsu Hengrui Pharmaceuticals Receives NMPA Approval for HRS-9815 Radiodiagnostic Drug Clinical Study

Fineline Cube Jul 11, 2023

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a China-based pharmaceutical company, has announced receiving approval...

Company Deals

Everest Medicines and Sinopharm Group Ink MoU to Enhance Distribution and Collaboration

Fineline Cube Jul 11, 2023

China-based Everest Medicines (HKG: 1952) has announced the signing of a memorandum of understanding (MoU)...

Posts pagination

1 … 449 450 451 … 611

Recent updates

  • AstraZeneca Secures Full Global Rights to AbelZeta’s C‑CAR031 in $630M CAR‑T Deal
  • Novartis’s Ianalumab Wins FDA Breakthrough Therapy Designation for Sjögren’s Disease
  • Medtronic and Precision Neuroscience Form First Brain‑Device Alliance to Access Neural Data
  • Akeso’s Gumokimab NMPA Filing for Ankylosing Spondylitis Expands IL‑17A Franchise
  • Harbour BioMed Boosts Spruce Stake to 3.8%, Advancing SPR202 for Adrenal Disease
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

AstraZeneca Secures Full Global Rights to AbelZeta’s C‑CAR031 in $630M CAR‑T Deal

Company Drug

Novartis’s Ianalumab Wins FDA Breakthrough Therapy Designation for Sjögren’s Disease

Company Deals

Medtronic and Precision Neuroscience Form First Brain‑Device Alliance to Access Neural Data

Company Drug

Akeso’s Gumokimab NMPA Filing for Ankylosing Spondylitis Expands IL‑17A Franchise

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.